Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LCK | P06239 | 19/20 | 0.65 |
| ▸ | FYN | P06241 | 1/20 | 0.58 |
| ▸ | SRC | P12931 | 1/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.57 |
| ▸ | NPC1 | O15118 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.57 |
| ▸ | HPGD | P15428 | 1/20 | 0.57 |
| ▸ | RAB9A | P51151 | 1/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6057725 | 0.94 | LCK (0.59) | LCKKDM4ENPC1ALDH1A1HPGD | |
| SCHEMBL6058087 | 0.92 | LCK (0.72) | LCKFYNSRCKDM4ENPC1 | |
| SCHEMBL6057946 | 0.88 | KDM4E (0.61) | LCKKDM4ENPC1ALDH1A1HPGD | |
| SCHEMBL6058324 | 0.86 | LCK (0.62) | LCKKDM4ENPC1ALDH1A1HPGD | |
| SCHEMBL6057893 | 0.86 | LCK (0.75) | LCKFYNSRC | |
| SCHEMBL6058161 | 0.84 | LCK (0.73) | LCKFYNSRCKDM4ENPC1 | |
| SCHEMBL6057953 | 0.83 | LCK (0.66) | LCKFYNSRC | |
| SCHEMBL6058188 | 0.82 | LCK (0.75) | LCKFYNSRC | |
| SCHEMBL6058122 | 0.81 | LCK (0.74) | LCKFYNSRC | |
| SCHEMBL6058250 | 0.80 | LCK (0.73) | LCKFYNSRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1037632-B1 | BENZOTHIAZOLE PROTEIN TYROSINE KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2006-01-11 | — | — | EP | claimed |
| US-6825355-B2 | FOR THERAPY OF IMMUNOLOGIC DISORDERS SUCH AS TRANSPLANT REJECTION, RHEUMATOID ARTHRITIS. MULTIPLE SCLEROSIS, INFLAMMATORY BOWEL DISEASE, LUPUS, GRAFT VS. HOST DISEASE | BRISTOL-MYERS SQUIBB CO. | 2004-11-30 | — | — | US | claimed |
| US-6825355-B2 | FOR THERAPY OF IMMUNOLOGIC DISORDERS SUCH AS TRANSPLANT REJECTION, RHEUMATOID ARTHRITIS. MULTIPLE SCLEROSIS, INFLAMMATORY BOWEL DISEASE, LUPUS, GRAFT VS. HOST DISEASE | BRISTOL-MYERS SQUIBB CO. | 2004-11-30 | — | — | US | disclosed |
| EP-1037632-A4 | BENZOTHIAZOLE PROTEIN TYROSINE KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2002-08-21 | — | — | EP | disclosed |
| EP-1037632-A1 | BENZOTHIAZOLE PROTEIN TYROSINE KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2000-09-27 | — | — | EP | disclosed |
| WO-1999024035-A1 | BENZOTHIAZOLE PROTEIN TYROSINE KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 1999-05-20 | — | — | WO | disclosed |